Relay Therapeutics (RLAY) Net Cash Flow (2019 - 2026)

Relay Therapeutics (RLAY) has 8 years of Net Cash Flow data on file, last reported at $120.6 million in Q1 2026.

• On a quarterly basis, Net Cash Flow rose 492.16% year-over-year to $120.6 million in Q1 2026; TTM through Mar 2026 was $109.6 million, a 282.95% increase from a year earlier, with the FY2025 full-year figure at -$41.1 million, down 104.88% from the prior year.
• Net Cash Flow for Q1 2026 stood at $120.6 million, up from -$8.5 million in the prior quarter.
• Over the last five years, Net Cash Flow for RLAY reached as high as $246.9 million in Q3 2022 and fell as low as -$202.8 million in Q4 2022.
• Historically, Net Cash Flow has averaged -$4.6 million across 5 years, with a median of -$8.5 million in 2025.
• On a YoY basis, Net Cash Flow climbed as much as 883.58% in 2022 and fell as far as 1131.23% in 2022.
• Year by year, Net Cash Flow stood at -$202.8 million in 2022, then soared by 96.26% to -$7.6 million in 2023, then plunged by 269.73% to -$28.1 million in 2024, then soared by 69.83% to -$8.5 million in 2025, then surged by 1523.84% to $120.6 million in 2026.
• Per Business Quant data, the three most recent Net Cash Flow figures were $120.6 million in Q1 2026, -$8.5 million in Q4 2025, and -$22.4 million in Q3 2025.